Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and lenalidomide or thalidomide. Patients were randomly...

Descripción completa

Detalles Bibliográficos
Autores principales: Spicka, Ivan, Ocio, Enrique M., Oakervee, Heather E., Greil, Richard, Banh, Raymond H., Huang, Shang-Yi, D’Rozario, James M., Dimopoulos, Meletios A., Martínez, Sara, Extremera, Sonia, Kahatt, Carmen, Alfaro, Vicente, Carella, Angelo M., Meuleman, Nathalie, Hájek, Roman, Symeonidis, Argiris, Min, Chang-Ki, Cannell, Paul, Ludwig, Heinz, Sonneveld, Pieter, Mateos, María Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700046/
https://www.ncbi.nlm.nih.gov/pubmed/31240472
http://dx.doi.org/10.1007/s00277-019-03739-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700046/
https://www.ncbi.nlm.nih.gov/pubmed/31240472
http://dx.doi.org/10.1007/s00277-019-03739-2

Ejemplares similares